文献速递衰弱、肌少症与跌倒

血浆C端集聚蛋白片段作为肌少症早期生物标志物:GenoFit研究结果

Plasma C-Terminal Agrin Fragment as an Early Biomarker for Sarcopenia: Results From the GenoFit Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2021-01-01

结果显示CAF与四肢骨骼肌量(ALM)显著相关但与握力无关,肌少症者CAF显著升高,低握力或低ALM者CAF亦升高,提示CAF可能作为骨骼肌健康的可及性生物标志物。

要点

  • 血浆CAF浓度与四肢骨骼肌量显著相关,但与握力无显著关联。
  • 肌少症患者血浆CAF浓度显著高于非肌少症者(p < .001)。
  • 低握力或低ALM者CAF升高,男性两者均升高,女性仅低ALM者升高。

核心结论

  • 血浆CAF可能是骨骼肌健康的一种可及性生物标志物,有助于促进肌少症更广泛的治疗策略。
  • CAF浓度的诊断相关性仍需未来研究确认其用于肌少症筛查的适用性。

研究设计与样本

  • 肌少症按欧洲老年人肌少症工作组(EWGSOP)标准诊断。
  • 体成分用双能X线吸收法(DXA)评估,肌力用手握力计检查,血浆CAF浓度用市售ELISA试剂盒测定。

主要发现

  • CAF浓度与四肢骨骼肌量(ALM)显著相关(p = .028),与握力无显著关联(p = .575)。
  • 肌少症个体血浆CAF浓度显著高于非肌少症者(p < .001)。
  • 校正年龄和体质指数后,低握力或低ALM者CAF水平显著高于健康对照(p = .027,p = .003)。
  • 男性中低握力或低ALM者CAF显著升高(p = .039,p = .027);女性中仅低ALM者CAF显著升高(p = .035)。

关键数值与推荐

  • 肌少症诊断依据欧洲老年人肌少症工作组(EWGSOP)标准。
  • CAF与ALM关联的显著性为p = .028,与握力关联的显著性为p = .575。
  • 肌少症与非肌少症者CAF比较的显著性为p < .001。
  • 校正年龄和体质指数后,低握力者CAF比较p = .027,低ALM者CAF比较p = .003。
  • 男性低握力者p = .039、低ALM者p = .027;女性低ALM者p = .035。

临床怎么用

  • CAF检测可能作为肌少症筛查的可及性生物标志物辅助临床识别骨骼肌健康风险。
  • CAF测定有望促进肌少症更广泛治疗策略的实施。

局限性

  • CAF浓度用于肌少症筛查的诊断相关性尚需未来研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Barriers associated with direct muscle quantification have prevented a consistent implementation of therapeutic measures for sarcopenia. Recently, the relevance of circulating C-terminal agrin fragment (CAF) as an accessible screening method alternative for sarcopenia has gained credence. Accordingly, this study aimed to verify the pertinence of plasma CAF as a biomarker for sarcopenia. Three hundred healthy adults aged between 50 and 83 years took part in this study. Sarcopenia was diagnosed according to the European Working Group on Sarcopenia in Older People criteria. Body composition was assessed using dual-energy x-ray absorptiometry, while muscle strength was examined using hand dynamometry. Plasma CAF concentrations were determined using a commercially available ELISA kit. CAF concentrations were significantly associated with appendicular lean mass (ALM), but not grip strength (p = .028, p = .575, respectively). Plasma CAF concentrations were significantly elevated in sarcopenic individuals compared to nonsarcopenic (p < .001). Overall, individuals with low grip strength or low ALM displayed significantly higher CAF levels compared to healthy controls, after adjusting for age and body mass index (p = .027, p = .003, respectively). In males, those with low grip strength or low ALM had significantly elevated CAF levels (p = .039, p = .027, respectively), while in females, only those with low ALM had significantly raised CAF concentrations, compared to healthy controls (p = .035). Our findings illuminate the potential relevance of CAF as an accessible biomarker for skeletal muscle health. CAF determination may enhance clinical practice by facilitating more widespread treatment strategies for sarcopenia. Nevertheless, future research is needed to confirm the diagnostic pertinence of CAF concentrations in screening for sarcopenia.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Pratt J, De Vito G, Narici M, et al. Plasma C-Terminal Agrin Fragment as an Early Biomarker for Sarcopenia: Results From the GenoFit Study. J Gerontol A Biol Sci Med Sci. 2021. PMID: 33993303. doi:10.1093/gerona/glab139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。